First oral postpartum depression drug approved as insurers weigh coverage

Health Canada has approved zuranolone, sold under the brand name Zurzuvae, as the first oral treatment for moderate to severe postpartum depression. Biogen Canada, which manufactures the drug, is actively working with private insurance providers to secure coverage for patients.

Because the treatment costs US$16,000 for the two-week course, insurance coverage will be critical to ensure timely access. Biogen said it is also establishing a patient support program to help individuals without private insurance or those unable to afford out-of-pocket costs.

Discussions with the public drug sector may follow, although coverage through public plans is not yet confirmed.

In Canada, private insurers often assess new, high-cost medications on a case-by-case basis. Coverage decisions depend on clin